Advertisement

Topics

Faber Maunsell - Bristol Company Profile

23:13 EDT 18th June 2018 | BioPortfolio

Faber Maunsell operates in the fields of building, transportation and environmental engineering consulting. With a broad range of skills and disciplines, we provide technical excellence across the full service spectrum, from strategic consultancy at the highest level to practical design, implementation and asset management.In essence, we help to design the built environment for the future. Every day, Faber Maunsell professionals use their expertise to develop bridges, tunnels, railways, roads, office buildings, leisure facilities, water distribution systems, laboratories, retail parks and transport networks, all of which play a central role in any nation's economy.In the UK and Europe, we employ over 2,500 people through a network of over 30 office locations. We are part of the AECOM Technology Corporation, a leading worldwide provider of professional technical services. AECOM, through its operating companies, collectively provides a full range of financial and technical resources, which are now deployed through 24,000 employees in over 60 countries around the world.

Location

Bush House Prince Street
Bristol
Somerset
BS1 4QD
United Kingdom

Contact

Phone: 44.(0)117.901.7000
Email: enquiries@fabermaunsell.com


News Articles [506 Associated News Articles listed on BioPortfolio]

Bristol-Myers Immune Drug Combo Hits Early Mark in Lung Cancer Study

A combination of two Bristol-Myers Squibb immunotherapies has achieved the main goal of a late-stage study in lung cancer, according to preliminary results the company released on Monday. Bristol said...

Bristol Partners With Illumina On Diagnostic Test To Use With Opdivo

Drug giant Bristol-Myers Squibb is partnering with Illumina, the leading maker of DNA sequencing gear, to develop diagnostic tests that will pair with Bristol's cancer drugs.

Bristol-Myers Squibb And Nektar To Collaborate On Immuno-Oncology Program

NewsUnder the collaboration, Bristol-Myers Squibb will pay Nektar Therapeutics $1.85 billion upfront. The companies will jointly develop and commercialize NKTR-214 in combination with Bristol-Myers Sq...

Bristol-Myers meldet Erfolg bei Krebsstudie: Der US-Pharmakonzern Bristol-Myers meldet Fortschritte ...

Der US-Pharmakonzern Bristol-Myers meldet Fortschritte bei seiner Krebstherapie Opdivo. Das gibt der Aktie kräftig Rückenwind.Der US-Pharmakonzern Bristol-Myers hat in einer wichtigen Studie mit se....

Bristol to lead revolutionary research into 'self-healing' materials

(University of Bristol) A consortium of seven institutions led by the University of Bristol, has received a grant of £2.7 million to undertake ground-breaking research into manufacturing new material...

Bogus cosmetic surgeon used ‘fake Botox’ from China on Bristol grandmother – Bristol Live

Bristol LiveBogus cosmetic surgeon used 'fake Botox' from China on Bristol grandmotherBristol LiveA bogus cosmetic surgeon who used 'fake Botox' on a Bristol grandmother has been jailed for four years...

Bristol researchers use gene editing to improve red blood cell transfusion compatibility

(University of Bristol) Synthetic biologists at the University of Bristol have succeeded in generating laboratory-made red blood cells with rare blood group types that could one day be used to help pa...

Bristol University English student Ben Murray dies ‘suddenly and unexpectedly’ – Bristol Live

Bristol LiveBristol University English student Ben Murray dies 'suddenly and unexpectedly'Bristol LiveAn English student at Bristol University has died 'suddenly and unexpectedly', it has been confirm...

Clinical Trials [72 Associated Clinical Trials listed on BioPortfolio]

Investigation of Hypermobility, Biomarkers, and Pain Generators in Chronic Pain Patients

Observational study of axial spine pain and hyperflexibility. Patients will receive physical exam maneuvers (traditional straight leg raise, FABER, facet loading as well as Beighton's hype...

Bioequivalence Study of Daclatasvir From Prodactariv 60 mg Film Coated Tablets (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Prodactariv 60 mg F.C.T (International Drug Agency for Pha...

Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European Egyptian Ph...

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

- Objective: - A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Co...

Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions

The objective of this study is to assess the single - dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fed conditions.

Companies [99 Associated Companies listed on BioPortfolio]

Faber Maunsell - Bristol

Faber Maunsell operates in the fields of building, transportation and environmental engineering consulting. With a broad range of skills and disciplines, we provide technical excellence across the ful...

Bristol-Myers Squibb and Pfizer

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Pfizer Inc. & Bristol-Myers Squibb

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Bristol-Myers Squibb Company and Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis, an oral anticoagulant discovered by Bristol-Myers Squibb. Thi...

Bristol-Myers Squibb Company & Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize ELIQUIS, an investigational oral anticoagulant discovered by Bristol-M...

More Information about "Faber Maunsell - Bristol" on BioPortfolio

We have published hundreds of Faber Maunsell - Bristol news stories on BioPortfolio along with dozens of Faber Maunsell - Bristol Clinical Trials and PubMed Articles about Faber Maunsell - Bristol for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Faber Maunsell - Bristol Companies in our database. You can also find out about relevant Faber Maunsell - Bristol Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record